ストックスクリーナーアプリを入手
37.47
1.26%
-0.48
プレマーケット:
37.34
-0.13
-0.35%
Artivion Inc (AORT) 最新ニュース
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st
Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat
Ladenburg Thalmann upgrades Artivion (AORT) - MSN
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 85 Tel - GuruFocus
LADENBURG THALM/SH SH Upgrades Artivion (NYSE:AORT) to Buy - MarketBeat
Endospan’s FDA nod for Nexus brings acquisition by Artivion closer - BioWorld News
Growth Value: Is Artivion Inc a momentum stock2026 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Artivion Receives FDA Clearance for NEXUS Aortic Arch System - Bitget
Artivion Secures FDA Approval for NEXUS Aortic Arch System - Zacks Investment Research
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Artivion, Inc. (AORT) Stock forecasts - Yahoo Finance UK
FDA Greenlights Artivion's (AORT) Nexus Aortic Arch System - GuruFocus
Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion - Yahoo Finance
Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus
Needham reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Needham reiterates Artivion stock rating on FDA approval - Investing.com
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com Australia
Artivion stock gets FDA approval for NEXUS stent graft system - Investing.com
FDA approves Artivion’s NEXUS system for aortic arch disease - Investing.com
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $58 - Moomoo
FDA approves Artivion’s NEXUS system for aortic arch disease By Investing.com - Investing.com South Africa
Artivion Says FDA Approves NEXUS Aortic Arch System, Secures Option to Acquire Endospan - marketscreener.com
Artivion announces U.S. FDA approval of the Nexus® aortic arch system - marketscreener.com
Artivion Announces U.S. FDA Approval Of The Nexus® Aortic Arch System - TradingView — Track All Markets
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System - ChartMill
Analyst Downgrade: What is the long term forecast for Artivion Inc stockWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Why Artivion (AORT) Stock Is Down Today - Yahoo Finance
Artivion Inc (AORT) Trading Down 3.24% on Apr 6 - GuruFocus
SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT - MarketBeat
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion, Inc. (AORT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Holloway Jean F, Artivion SVP, sells $83k in shares - Investing.com
Artivion Inc Com (AORT) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Artivion (NYSE:AORT) Shares Gap DownShould You Sell? - MarketBeat
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks - Yahoo Finance
JPMorgan Chase & Co. Has $5.17 Million Position in Artivion, Inc. $AORT - MarketBeat
Is It Too Late To Consider Artivion (AORT) After A 161.6% Three Year Rally? - Yahoo Finance
How The Artivion (AORT) Narrative Is Shifting After A Trimmed Target And Steady Fair Value - Yahoo Finance
Artivion, Inc. (AORT) Stock Forecasts - Yahoo Finance
EDGAR Filing Documents for 0001999371-26-007510 - SEC.gov
Artivion (AORT) details 2026 virtual meeting, director slate and Say on Pay - Stock Titan
[ARS] ARTIVION, INC. SEC Filing - Stock Titan
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):